Tag: ASCO
ASCO: AstraZeneca’s Tagrisso, headed for big sales boost, cuts lung cancer...
In mid-April, at the recommendation of an independent data monitoring committee, AstraZeneca unblinded a phase 3 trial of Tagrisso two years early. Now, the...
ASCO: Pfizer, Merck KGaA’s Bavencio posts win in rare gynecological cancer
Pfizer and Merck KGaA’s Bavencio is having itself an ASCO. In addition to putting up game-changing results in bladder cancer, it’s posted a win...
Legend aims for $100M IPO as partner J&J mulls outpatient use...
The Chinese company that originally created a CAR-T for multiple myeloma now under clinical development by Johnson & Johnson is planning to go public,...
Amgen data on drug with ‘undruggable’ target at ASCO gets muted...
Amgen’s booth at the 2019 ASCO conference in Chicago
A leading contender in the race to develop drugs that target a type of commonly expressed...
ASCO: Roche’s Alecensa stays on top of Xalkori with long-term survival...
Roche made a splash at ASCO three years ago with data showing that its Alecensa could top Pfizer’s Xalkori at keeping ALK-positive lung-cancer at bay....
